These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 39066209)

  • 21. Immunogenicity and antimicrobial effectiveness of Pseudomonas aeruginosa specific bacteriophage in a human lung in vitro model.
    Shiley JR; Comfort KK; Robinson JB
    Appl Microbiol Biotechnol; 2017 Nov; 101(21):7977-7985. PubMed ID: 28914348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual Predation by Bacteriophage and
    Hobley L; Summers JK; Till R; Milner DS; Atterbury RJ; Stroud A; Capeness MJ; Gray S; Leidenroth A; Lambert C; Connerton I; Twycross J; Baker M; Tyson J; Kreft JU; Sockett RE
    J Bacteriol; 2020 Feb; 202(6):. PubMed ID: 31907203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel N4-Like Bacteriophage Isolated from a Wastewater Source in South India with Activity against Several Multidrug-Resistant Clinical Pseudomonas aeruginosa Isolates.
    Menon ND; Kumar MS; Satheesh Babu TG; Bose S; Vijayakumar G; Baswe M; Chatterjee M; D'Silva JR; Shetty K; Haripriyan J; Kumar A; Nair S; Somanath P; Nair BG; Nizet V; Kumar GB
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions.
    Alves DR; Perez-Esteban P; Kot W; Bean JE; Arnot T; Hansen LH; Enright MC; Jenkins AT
    Microb Biotechnol; 2016 Jan; 9(1):61-74. PubMed ID: 26347362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo.
    Ashworth EA; Wright RCT; Shears RK; Wong JKL; Hassan A; Hall JPJ; Kadioglu A; Fothergill JL
    Nat Commun; 2024 Feb; 15(1):1547. PubMed ID: 38378698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
    Chang RYK; Chen K; Wang J; Wallin M; Britton W; Morales S; Kutter E; Li J; Chan HK
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled phage therapy by photothermal ablation of specific bacterial species using gold nanorods targeted by chimeric phages.
    Peng H; Borg RE; Dow LP; Pruitt BL; Chen IA
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):1951-1961. PubMed ID: 31932441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Spatial Heterogeneity of the Gut Limits Predation and Fosters Coexistence of Bacteria and Bacteriophages.
    Lourenço M; Chaffringeon L; Lamy-Besnier Q; Pédron T; Campagne P; Eberl C; Bérard M; Stecher B; Debarbieux L; De Sordi L
    Cell Host Microbe; 2020 Sep; 28(3):390-401.e5. PubMed ID: 32615090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
    Jault P; Leclerc T; Jennes S; Pirnay JP; Que YA; Resch G; Rousseau AF; Ravat F; Carsin H; Le Floch R; Schaal JV; Soler C; Fevre C; Arnaud I; Bretaudeau L; Gabard J
    Lancet Infect Dis; 2019 Jan; 19(1):35-45. PubMed ID: 30292481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "I will survive": A tale of bacteriophage-bacteria coevolution in the gut.
    De Sordi L; Lourenço M; Debarbieux L
    Gut Microbes; 2019; 10(1):92-99. PubMed ID: 29913091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the Interplay between Nutrients, Bacteriophages, and Bacterial Lipases in Host- and Bacteria-mediated Pathogenesis.
    Ghadimi D; Fölster-Holst R; Ebsen M; Röcken C; Dörfer C; Uchiyama J; Matsuzaki S; Bockelmann W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(8):930-945. PubMed ID: 37957846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High throughput platform technology for rapid target identification in personalized phage therapy.
    Bayat F; Hilal A; Thirugnanasampanthar M; Tremblay D; Filipe CDM; Moineau S; Didar TF; Hosseinidoust Z
    Nat Commun; 2024 Jul; 15(1):5626. PubMed ID: 38992046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parallel evolution of
    Castledine M; Padfield D; Sierocinski P; Soria Pascual J; Hughes A; Mäkinen L; Friman VP; Pirnay JP; Merabishvili M; de Vos D; Buckling A
    Elife; 2022 Feb; 11():. PubMed ID: 35188102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phage therapy in gut microbiome.
    Chen X; Mendes BG; Alves BS; Duan Y
    Prog Mol Biol Transl Sci; 2023; 201():93-118. PubMed ID: 37770177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subdiffusive motion of bacteriophage in mucosal surfaces increases the frequency of bacterial encounters.
    Barr JJ; Auro R; Sam-Soon N; Kassegne S; Peters G; Bonilla N; Hatay M; Mourtada S; Bailey B; Youle M; Felts B; Baljon A; Nulton J; Salamon P; Rohwer F
    Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13675-80. PubMed ID: 26483471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition.
    Cornuault JK; Moncaut E; Loux V; Mathieu A; Sokol H; Petit MA; De Paepe M
    ISME J; 2020 Mar; 14(3):771-787. PubMed ID: 31827247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivering phage therapy per os: benefits and barriers.
    Zelasko S; Gorski A; Dabrowska K
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered Superinfective Pf Phage Prevents Dissemination of Pseudomonas aeruginosa in a Mouse Burn Model.
    Prokopczuk FI; Im H; Campos-Gomez J; Orihuela CJ; Martínez E
    mBio; 2023 Jun; 14(3):e0047223. PubMed ID: 37039641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbiome-phage interactions in inflammatory bowel disease.
    Federici S; Kviatcovsky D; Valdés-Mas R; Elinav E
    Clin Microbiol Infect; 2023 Jun; 29(6):682-688. PubMed ID: 36191844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways.
    Trend S; Fonceca AM; Ditcham WG; Kicic A; Cf A
    J Cyst Fibros; 2017 Nov; 16(6):663-670. PubMed ID: 28720345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.